Sebastián Chiavenna

Principal

2023

Criteria Bio Ventures is a leading life sciences venture fund investing in transformative companies to shape the future of healthcare. CBV teams up with driven entrepreneurs and fellow investors to build innovative companies with the potential to transform patients’ lives. CBV invests in global biotech companies that provide disruptive therapeutic approaches centered on addressing unmet medical needs, with a primary focus on Europe. Criteria Bio Ventures is part of Caixa Capital Risc and the CriteriaCaixa group, Spanish largest investment holding with over €25 billion in Assets Under Management.

Principal

2023

Caixa Capital Risc is the venture capital arm of CriteriaCaixa, an investor that provides equity to innovative companies through different specialized vehicles. In Life Science, we primarily invest in companies that boast disruptive technologies and that have committed and experienced management team. Our sweet spot is preclinical stage, but we can entry earlier when highly disruptive technologies are in place.

Senior Associate - Life Science Investment Funds

2020 - 2022

Board Director

2022

Inbiomotion focuses on providing a unique companion diagnostic solution, to address an urgent and unmet medical need in the personalized adjuvant treatment of early-stage breast cancer. The diagnostic assay is based on MAF gene that has the potential to identify early-stage breast cancer patients who will benefit from bisphosphonate adjuvant treatment.

Innovation Selection Board Member

2024 - 2024

Innovation Selection Board member at CaixaImpulse Innovation 2024 which is a program led by Fundación "la Caixa" that helps to transfer scientific knowledge to society and encourages the creation of new products, services and companies related to life sciences. It supports innovative biomedical projects by helping them to validate their asset/s and define their valorisation and exploitation strategy, and by bringing them closer to the market.

Innovation Selection Board Member

2023 - 2023

Innovation Selection Board member at CaixaImpulse Innovation 2023 which is a program led by Fundación "la Caixa" that helps to transfer scientific knowledge to society and encourages the creation of new products, services and companies related to life sciences. It supports innovative biomedical projects by helping them to validate their asset/s and define their valorisation and exploitation strategy, and by bringing them closer to the market.

Board Director

2021 - 2023

GlyCardial works to improve the early diagnosis of cardiac ischemic events to reduce the impact of the disease on patients' life. The technology is based on the detection of glycosylated Apolipoprotein J (ApoJ-Glyc) in blood as a biomarker for the early diagnosis of cardiac ischemia and the prediction of patients' evolution after an ischemic event.

Board Observer

2020 - 2021

Senior Corporate Marketing Manager

2018 - 2020

As Corporate Marketing Manager, reporting to the Corporate Strategy and Market Access Director, I led a multifunctional brand team to set up the marketing strategy for products in the hospital setting that the company commercialize worldwide. Main activities and responsibilities: • lead the brand team to achieve goals in time frame • conduct the market research and set up the marketing strategy for hospital setting products • train the sales team and subsidiaries in EU regarding marketing strategy • build long term relationships with international KOL’s • represent the company in international scientific congresses Marketing ǀ Project Management ǀ Business Development ǀ Biotechnology ǀ Oncology

Head of Project Development

2014 - 2018

As Head of Project Development, reporting to the Ferrer Advanced Biotherapeutics Director, I was in charge of scouting R&D projects ensuring they were aligned with the strategy of the company. I oversaw the lifecycle of five to obtain milestones in time frame. One of the programs reached the market in 2017 (EPICUP). Main responsibilities: • scout R&D projects ensuring they are aligned with the strategy of the company • analyze the feasibility/profitability of the projects, evaluating their technical and financial risks • conduct the market research and develop the marketing plan when the product is finished • manage the R&D projects through all the development steps • coordinate teamwork with different functional units in the company and with the academia • initiate and follow up clinical trials • build long term relationships with KOL’s • represent the company in scientific international congresses and business meetings Marketing ǀ Project Management ǀ Business Development ǀ Biotechnology ǀ Oncology

Medical Advisor for Biotechnology

2010 - 2013

As Medical Advisor for Biotechnology, I leaded the 5 members Medical Scientific Liaison (MSL) team. I managed five products in oncology (three for breast cancer, one for colorectal cancer and one for cancer of unknown primary) and, one product in hepatology. I reported to the Medical and Marketing Directors. Main responsibilities: • lead the MSL team formed by 5 members • train and support the different functional units in the company and partners in EU and LATAM • conduct conferences in health care institutions and scientific meetings • initiate and follow up clinical trials • build long term relationships with local health care authorities (market access) and KOL’s • represent the company in scientific international congresses Marketing ǀ Project Management ǀ Business Development ǀ Biotechnology ǀ Oncology

Scientific Marketing Manager

2008 - 2010

As Scientific Marketing Manager, reporting to the Marketing & Commertial Director, I co-leaded the sales team formed by 6 sales reps. I managed three products in cardiology to weight the cardiovascular risk, the thromboembolism risk and the sudden cardiac death risk and, one product in nutrigenomics to weight the obesity risk. Main responsibilities: • co-lead the commercial team formed by 6 sales reps • set up the marketing strategy and tactics for the products in the portfolio • conduct the market research and develop the marketing plan • to train the sales team and partners in EU and LATAM regarding scientific and marketing issues • conduct conferences in health care institutions and scientific meetings • build long term relationships with local health care authorities (market access) and KOL’s • represent the company in scientific international congresses Marketing ǀ Project Management ǀ Business Development ǀ Biotechnology ǀ Oncology

PhD fellow

2002 - 2007

Being a PhD fellow I worked on Bovine Viral Diarrhea Virus (BVDV), a Pestivirus of the Flaviviridae family, that is an important cause of morbidity, mortality and economical losses in cattle worldwide. I carried out my research focusing on the E2 protein, the major glycoprotein of BVDV envelope and the main target for neutralising antibodies. My PhD thesis consisted to express this glicoprotein from NADL strain in two different stable systems, Alfalfa transgenic plants and a mammalian cell line. The promising results helped the lab to signed off a collaborative research agreement with a veterinary industry company.